- Home
- RMR vs QTTB Comparison
RMR vs QTTB Comparison
Compare RMR & QTTB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RMR | QTTB |
|---|---|---|
| Founded | 1986 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Professional Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 312.9M | 265.2M |
| IPO Year | 2015 | 2018 |
Fundamental Metrics
Financial Performance| Metric | RMR | QTTB |
|---|---|---|
| Price | $16.70 | $8.97 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 7 |
| Target Price | $22.50 | ★ $39.67 |
| AVG Volume (30 Days) | 127.3K | ★ 519.2K |
| Earning Date | 11-12-2026 | 11-04-2026 |
| Dividend Yield | ★ 10.84% | N/A |
| EPS Growth | N/A | ★ 136.78 |
| EPS | ★ 0.95 | N/A |
| Revenue | ★ $700,284,000.00 | $53,737,000.00 |
| Revenue This Year | $221.97 | N/A |
| Revenue Next Year | $4.87 | $150.00 |
| P/E Ratio | $17.46 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $14.73 | $1.91 |
| 52 Week High | $21.45 | $23.57 |
Technical Indicators
Market Signals| Indicator | RMR | QTTB |
|---|---|---|
| Relative Strength Index (RSI) | 33.20 | 46.44 |
| Support Level | $16.19 | $7.45 |
| Resistance Level | $17.44 | $9.16 |
| Average True Range (ATR) | 0.47 | 0.50 |
| MACD | -0.07 | 0.21 |
| Stochastic Oscillator | 8.06 | 71.54 |
Price Performance
Historical ComparisonAbout RMR The RMR Group Inc.
The RMR Group Inc is a U.S. based real estate investment manager engaged in commercial real estate, private capital, and credit strategies. Its portfolio covers various commercial real estate asset classes, and it manages investments across various industries, geographies and asset classes.
About QTTB Q32 Bio Inc.
Q32 Bio Inc is a clinical-stage biotechnology company focused on developing novel biologics to restore healthy immune balance in patients with alopecia areata (AA) and other autoimmune and inflammatory diseases driven by immune dysfunction. Its product candidate, bempikibart (ADX 914), is a fully human anti-interleukin 7 receptor alpha (IL-7R) antagonist monoclonal antibody designed to block signaling mediated by interleukin 7 (IL 7) and thymic stromal lymphopoietin (TSLP) and re-regulate adaptive immune function. The company has completed two Phase 2a clinical trials evaluating bempikibart, SIGNAL AA Part A for the treatment of alopecia areata and SIGNAL AD for the treatment of atopic dermatitis (AD).